Form 4: Akebia Therapeutics Director Ron Frieson Receives Stock Options and Restricted Stock Units

Director Ron Frieson of Akebia Therapeutics received 30,000 restricted stock units and options to purchase 45,000 shares of common stock on June 6, 2024.

Summary

• On June 6, 2024, Ron Frieson, a director at Akebia Therapeutics, received 30,000 restricted stock units (RSUs) and an option to purchase 45,000 shares of Akebia's common stock.
• The RSUs were granted under the company's 2023 Stock Incentive Plan and Third Amended and Restated Non-Employee Director Compensation Program.
• The RSUs will vest fully on the first anniversary of the grant date or immediately before the first annual meeting of stockholders after the grant date, contingent on Frieson's continued service.
• The stock option, also granted under the same plan and program, has an exercise price of $1.07 and will vest and become exercisable fully on the first anniversary of the grant date or immediately before the first annual meeting of stockholders after the grant date, subject to continued service.
• Following these transactions, Frieson directly owns 73,700 shares of Akebia Therapeutics common stock and options to purchase 45,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral but positive signal.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This type of equity compensation is standard practice for directors of publicly traded companies to align their interests with shareholders.

Comparison to Industry Standards

• Equity grants to board members are a common practice in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options and RSUs as part of their director compensation packages.
• The vesting schedules and grant sizes are generally comparable to industry norms, aiming to incentivize long-term commitment and value creation.

Stakeholder Impact

• The equity grants align the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates